Stocks and Investing
Stocks and Investing
Mon, August 15, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Swayampakula Ramakanth Maintained (CASI) at Strong Buy with Increased Target to $12 on, Aug 15th, 2022
Swayampakula Ramakanth of HC Wainwright & Co., Maintained "CASI Pharmaceuticals, Inc." (CASI) at Strong Buy with Increased Target from $3 to $12 on, Aug 15th, 2022.
Swayampakula has made no other calls on CASI in the last 4 months.
There are 2 other peers that have a rating on CASI. Out of the 2 peers that are also analyzing CASI, 0 agree with Swayampakula's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Swayampakula
- Justin Zelin of "BTIG" Maintained at Strong Buy with Increased Target to $21 on, Friday, June 3rd, 2022
- Sean Lee of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $30 on, Monday, May 16th, 2022
Contributing Sources